Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing 100044, China.
Chin Med Sci J. 2020 Jun 30;35(2):157-169. doi: 10.24920/003565.
Objective Hilar cholangiocarcinoma (HC) is invariably fatal without surgical resection. The primary aim of the current study was to determine the safety of variable surgical resections for patient with HC and their survival after surgical resection. In addition, prognostic factor for the overall survival was also evaluated. Methods The study included 59 consecutive patients who were newly diagnosed with HC and underwent surgical resections with curative intend between February 2009 and February 2017. Patients were followed up at 3-6 months intervals after hospital discharge. Postoperative complications and overall survival were determined. Associations of clinicopathologic and surgeon-related factors with overall survival were evaluated through univariate analysis and Cox regression analysis. Results Of patients with Bismuth and Corlette (B & C) type Ⅲ (=19) and Ⅳ (=25) HC lesions, 33 (55.9%) were treated with hilar resection combined with major liver resection (MLR), while the other 11 patients with type Ⅲ and Ⅳ, and those with type Ⅰ (=8) and Ⅱ (=7) HC lesions were treated with hilar resection. The overall surgical mortality was 5.1% and surgical morbidity was 35.6%. There was no statistical difference in the mortality between MLR group and hilar resection group (6.1% 3.8%; =0.703, =0.145). The median follow-up period was 18 months (range, 1-94 months). The 1-, 3-, 5-year survival rate was 59.3%, 36.5%, and 17.7%, respectively. The overall survival after resections was 18 months. In HC patients with B & C type Ⅲ and Ⅳ lesions, the median survival was 23 months for hilar resection with MLR and 8 months for hilar resection alone; the 1-, 3-, 5-year cumulative survival rate was 63.9%, 23.3%, and 15.5%, respectively for hilar resection with MLR, and 11.1%, 0, and 0, respectively for hilar resection alone, with significant differene observed (, 9.902; 95% , 2.636-19.571, =0.001). Four factors were independently associated with overall survival: preoperative serum Ca19-9 (, 7.039; 95% , 2.803-17.678, <0.001), histopathologic grade (, 4.964; 95% , 1.046-23.552, =0.044), surgical margins (=0.031), and AJCC staging (=0.015). Conclusions R0 resection is efficacious in surgical treatment of HC. MLR in combination with caudate lobe resection may increase the chance of R0 resection and improve survival of HC patients with B & C type Ⅲ and Ⅳ lesions. Preoperatively prepared for biliary drainage may ensure the safety of MLR in most HC patients. Novel adjuvant therapies are needed to improve the survival of HC patients with poor prognostic factors.
肝门部胆管癌(HC)若不进行手术切除则无法根治,目前本研究的主要目的是明确不同手术切除方案治疗 HC 患者的安全性,以及手术后的生存情况。此外,还评估了总生存的预后因素。
本研究纳入了 2009 年 2 月至 2017 年 2 月期间新诊断为 HC 且接受根治性手术的 59 例患者。患者出院后每 3-6 个月随访一次,评估术后并发症和总生存情况。通过单因素分析和 Cox 回归分析评估临床病理和外科医生相关因素与总生存的关系。
Bismuth 和 Corlette(B & C)Ⅲ型(=19 例)和Ⅳ型(=25 例)HC 病变患者中,33 例(55.9%)接受了肝门部联合肝叶切除术(MLR)治疗,而其余 11 例Ⅲ型和Ⅳ型患者以及 8 例Ⅰ型(=8 例)和 7 例Ⅱ型(=7 例)HC 病变患者接受了肝门部切除术。总的手术死亡率为 5.1%,手术发病率为 35.6%。MLR 组和肝门部切除术组的死亡率无统计学差异(6.1% vs. 3.8%;=0.703,=0.145)。中位随访时间为 18 个月(范围 1-94 个月)。1、3、5 年生存率分别为 59.3%、36.5%和 17.7%。手术后的总生存时间为 18 个月。在 B & C Ⅲ型和Ⅳ型 HC 病变患者中,MLR 联合肝门部切除术的中位生存时间为 23 个月,单纯肝门部切除术为 8 个月;1、3、5 年累积生存率分别为 MLR 联合肝门部切除术 63.9%、23.3%和 15.5%,单纯肝门部切除术为 11.1%、0 和 0,差异有统计学意义(=9.902;95%=2.636-19.571,=0.001)。4 个因素与总生存独立相关:术前血清 Ca19-9(=7.039;95%=2.803-17.678,<0.001)、组织病理学分级(=4.964;95%=1.046-23.552,=0.044)、手术切缘(=0.031)和 AJCC 分期(=0.015)。
R0 切除是治疗 HC 的有效方法。MLR 联合尾状叶切除术可能增加 R0 切除的机会,并改善 B & C Ⅲ型和Ⅳ型 HC 病变患者的生存。术前做好胆道引流准备可以保证大多数 HC 患者 MLR 的安全性。需要新的辅助治疗方法来提高预后不良因素的 HC 患者的生存率。